Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...